Apixaban dosing study for people on peritoneal dialysis
Treatments studied
Part of Heart & circulation clinical trials.
This study checks how apixaban (a blood thinner) moves through the body in people who are on peritoneal dialysis and have non-valvular atrial fibrillation. It may help confirm the safest and most effective dosing for patients who have little or no remaining kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on stable peritoneal dialysis (PD)
- You have atrial fibrillation that is not related to a heart valve problem
- You have little to no remaining kidney function
- Your clinician does not think you have a high bleeding risk
- You do not have certain blood-thinner–not-safe situations, like recent bleeding or major recent injuries
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood thinners, apixaban and warfarin, in people on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). The goal is to see which one works better and is safer for preventing strokes.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study compares two ways to manage atrial fibrillation (an irregular heartbeat) in people on dialysis. One approach uses a blood thinner called apixaban, and the other does not use blood thinners. The goal is to see which approach better prevents strokes and bleeding.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.